Several other equities analysts have also issued reports on GRFS. Zacks Investment Research raised GRIFOLS S A/S from a sell rating to a hold rating in a report on Monday. JPMorgan Chase & Co. upgraded GRIFOLS S A/S from a neutral rating to an overweight rating and increased their target price for the stock from $21.00 to $22.50 in a research report on Thursday, June 27th. Finally, ValuEngine downgraded GRIFOLS S A/S from a hold rating to a sell rating in a research report on Thursday, August 1st. Four research analysts have rated the stock with a sell rating, three have assigned a hold rating and one has issued a buy rating to the stock. GRIFOLS S A/S has a consensus rating of Hold and a consensus price target of $20.75.
Shares of NASDAQ:GRFS traded down $0.24 during midday trading on Tuesday, reaching $20.48. The company’s stock had a trading volume of 100,495 shares, compared to its average volume of 1,296,572. The firm has a market capitalization of $14.19 billion, a price-to-earnings ratio of 17.51, a PEG ratio of 1.27 and a beta of 1.11. The company has a debt-to-equity ratio of 1.38, a quick ratio of 0.95 and a current ratio of 2.68. The firm has a 50 day moving average price of $21.76 and a two-hundred day moving average price of $20.08. GRIFOLS S A/S has a fifty-two week low of $17.42 and a fifty-two week high of $23.03.
GRIFOLS S A/S (NASDAQ:GRFS) last posted its quarterly earnings results on Wednesday, July 31st. The biotechnology company reported $0.33 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.33. GRIFOLS S A/S had a return on equity of 14.88% and a net margin of 11.82%. The business had revenue of $1.42 billion for the quarter, compared to the consensus estimate of $1.38 billion. As a group, research analysts anticipate that GRIFOLS S A/S will post 1.23 earnings per share for the current year.
Several hedge funds have recently modified their holdings of GRFS. Thomas White International Ltd. purchased a new stake in shares of GRIFOLS S A/S in the second quarter worth $84,000. Advisors Asset Management Inc. raised its position in shares of GRIFOLS S A/S by 40.8% in the first quarter. Advisors Asset Management Inc. now owns 5,108 shares of the biotechnology company’s stock worth $103,000 after buying an additional 1,479 shares in the last quarter. Assetmark Inc. raised its position in shares of GRIFOLS S A/S by 453.8% in the second quarter. Assetmark Inc. now owns 6,363 shares of the biotechnology company’s stock worth $134,000 after buying an additional 5,214 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its position in shares of GRIFOLS S A/S by 24.2% in the second quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 7,818 shares of the biotechnology company’s stock worth $165,000 after buying an additional 1,522 shares in the last quarter. Finally, First Light Asset Management LLC purchased a new stake in shares of GRIFOLS S A/S in the second quarter worth $215,000. Institutional investors own 17.99% of the company’s stock.
GRIFOLS S A/S Company Profile
Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes a range of biological medicines on plasma derived proteins worldwide. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use; and sells and distributes end products.
Further Reading: Cost of Debt
Receive News & Ratings for GRIFOLS S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRIFOLS S A/S and related companies with MarketBeat.com's FREE daily email newsletter.